Blanket Purchase Agreement 36F79719D0170-36C24823A0018
Award Date
4/1/23
Last Date to Order
12/31/27
Federal Agency
Veterans Integrated Service Network 8
Awardee
Progenics Pharmaceuticals Inc.
Ultimate Awardee
Lantheus Holdings, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) has awarded Blanket Purchase Agreements (BPAs) totaling over $4.3 million to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of PYLARIFY (piflufolastat F-18), a radiopharmaceutical used in positron emission tomography (PET) scans to detect prostate cancer. These BPAs, issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), allow various VA healthcare facilities across the Veterans...
The Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the provision of PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The single-award BPA, valued at $2,634,365.60, was established under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded a Blanket Purchase Agreement to Progenics Pharmaceuticals Inc. for PYLARIFY products and services. The single award BPA, valued at over $1.3 million, was issued on July 15, 2022 against the Pharmaceuticals and Drugs Federal Supply Schedule master contract for the period of July 15, 2022 through June 14, 2024. Performance will take place in New York, New York. The BPA calls authorize...
The key products and services being delivered under this Blanket Purchase Agreement (BPA) federal contract Indefinite Delivery Vehicle (IDV) are PYLARIFY (piflufolastat F-18), a radiopharmaceutical drug used for positron emission tomography (PET) imaging of prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and a subsidiary of Lantheus Holdings, Inc. The contract, valued at up to $1,188,615.44, was awarded by the U.S....
The Defense Health Agency (DHA) awarded a Blanket Purchase Agreement (BPA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The BPA has a ceiling value of $1,000,000 and a period of performance through January 31, 2028. The contract is not set aside for small businesses. Under this BPA, the DHA...
The key products and services being delivered under this federal contract IDV are PYLARIFY (piflufolastat F-18), a radiopharmaceutical drug used for positron emission tomography (PET) imaging of prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and a subsidiary of Lantheus Holdings, Inc. The contract vehicles include several Blanket Purchase Agreements (BPAs) awarded by the U.S. Department of Veterans Affairs (VA) and the...
The key products and services being delivered under this federal contract Indefinite Delivery Vehicle (IDV) award are radiopharmaceuticals, specifically F-18 PYLARIFY, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., a for-profit pharmaceutical company specializing in innovative diagnostic imaging agents. The $5,990,475.20 Indefinite...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a blanket purchase agreement and associated calls to Progenics Pharmaceuticals Inc. for the provision of radioactive drugs. The drugs are indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer and suspected metastasis. Under the agreement, Progenics Pharmaceuticals received a call contract valued at $721,744 with a...
The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY...
This is a $2,616,322.00 Indefinite Delivery Contract (IDC) awarded by the U.S. Department of Veterans Affairs (VA), specifically through Veterans Integrated Service Network (VISN) 9, to Pharmalogic Holdings Corp. (doing business as Pharmalogic Puerto Rico). The contract is for the delivery of PYLARIFY F-18 piflufolastat, a radiopharmaceutical used for prostate cancer imaging, to support the VA's nuclear medicine services and imaging programs for veterans. The contract has a 5-year performance...